Analysts Set LifeMD, Inc. (NASDAQ:LFMD) PT at $7.57

LifeMD, Inc. (NASDAQ:LFMD) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $7.5714.

A number of research analysts have recently issued reports on the company. Lake Street Capital set a $5.00 price target on LifeMD in a report on Thursday, August 6th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Mizuho set a $7.00 target price on shares of LifeMD in a report on Thursday, August 6th.

Institutional Investors Weigh In On LifeMD

Large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in LifeMD by 8.0% in the 2nd quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock worth $12,533,000 after purchasing an additional 225,510 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of LifeMD by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after purchasing an additional 140,749 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of LifeMD by 278.1% in the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after purchasing an additional 721,018 shares during the period. Geode Capital Management LLC boosted its holdings in LifeMD by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 959,700 shares of the company’s stock worth $3,273,000 after buying an additional 11,324 shares in the last quarter. Finally, Royce & Associates LP boosted its holdings in LifeMD by 11.7% during the fourth quarter. Royce & Associates LP now owns 909,651 shares of the company’s stock worth $3,102,000 after buying an additional 95,200 shares in the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Stock Performance

Shares of LFMD opened at $3.05 on Tuesday. The company has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.98. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $7.32. The stock has a market capitalization of $147.01 million, a PE ratio of -60.99 and a beta of 2.04.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The business had revenue of $47.28 million for the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. Equities research analysts forecast that LifeMD will post -0.46 EPS for the current year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.